Skip to main content

Table 1 Patients’ characteristics at the time of transplant in the study (n = 93) and lung transplant recipients with/without PRA (n = 23 vs 70, respectively)

From: The fraction of sensitization among lung transplant recipients in a transplant center in Japan

 

Total (n = 93)

PRA+ (n = 23)

PRA- (n = 70)

p-value

Age at LTX, median (IQR)

42 (32–50)

45 (33–50)

41 (31–49)

0.423

Sex, female

53 (57.0%)

13 (56.5%)

40 (75.5%)

1.000

LTX procedure

Single

48 (51.6%)

11 (47.8%)

37 (52.9%)

0.935

Double

37 (39.8%)

10 (43.5%)

27 (38.6%)

 

Living-donor

8 (8.6%)

2 (8.7%)

6 (8.6%)

 

LTX indication

Pulmonary vascular disease

21 (22.6%)

4 (17.4%)

17 (24.3%)

0.282

Restrictive lung disease

19 (20.4%)

7 (30.4%)

12 (17.1%)

 

Obstructive lung disease

39 (41.9%)

7 (30.4%)

32 (45.7%)

 

Suppurative lung disease

8 (8.6%)

4 (17.4%)

4 (5.7%)

 

CLAD

2 (2.2%)

0 (0%)

2 (2.9%)

 

Others

4 (4.3%)

1 (4.3%)

3 (4.3%)

 

Pre-LTX comorbidities

Diabetes

6 (6.5%)

1 (4.3%)

5 (7.1%)

1.000

Connective tissue disease

14 (15.1%)

6 (23.1%)

8 (11.4%)

0.102

GERD

5 (12.8%)

2 (8.7%)

3 (4.3%)

0.594

Chronic kidney diseasea

3 (3.3%)

1 (4.3%)

2 (2.9%)

1.000

  1. Abbreviation: PRA panel-reactive assay, IQR Interquartile range, LTX lung transplant, CLAD chronic lung allograft dysfunction, GERD gastroesophageal reflux disease
  2. aincalculable the glomerular filtration rate in 2 recipients (n = 91)